TY - JOUR
T1 - Impact of the combination of donor age and HLA disparity on the outcomes of unrelated bone marrow transplantation
AU - for the JSHCT Donor Source Working Group
AU - Seo, Sachiko
AU - Usui, Yoshiaki
AU - Matsuo, Keitaro
AU - Atsuta, Yoshiko
AU - Igarashi, Aiko
AU - Fukuda, Takahiro
AU - Ozawa, Yukiyasu
AU - Katayama, Yuta
AU - Yoshida, Shuro
AU - Uchida, Naoyuki
AU - Kondo, Tadakazu
AU - Kako, Shinichi
AU - Tsukada, Nobuhiro
AU - Kato, Shunichi
AU - Onizuka, Makoto
AU - Ichinohe, Tatsuo
AU - Kimura, Fumihiko
AU - Kanda, Yoshinobu
AU - Miyamura, Koichi
AU - Kanda, Junya
AU - Ago, Hiroatsu
AU - Imai, Kiyotoshi
AU - Uchida, Naoyuki
AU - Kato, Koji
AU - Kato, Shuichi
AU - Kanda, Yoshinobu
AU - Kanda, Junya
AU - Kuwatsuka, Yachiyo
AU - Kobayashi, Takeshi
AU - Sawa, Masashi
AU - Sunami, Kazutaka
AU - Seo, Sachiko
AU - Tanaka, Masatsugu
AU - Taniguchi, Shuichi
AU - Tabuchi, Ken
AU - Tsukada, Nobuhiro
AU - Terakura, Seitaro
AU - Nagata, Yasuyuki
AU - Nishiwaki, Satoshi
AU - Fujita, Naoto
AU - Matsuno, Ryosuke
AU - Matsumoto, Kimikazu
AU - Mitamura, Shin
AU - Miyamura, Koichi
AU - Morishima, Yasuo
AU - Yakushijin, Kimikazu
AU - Watanabe, Syudai
AU - Ishiyama, Ken
AU - Kimura, Fumihiko
AU - Kataoka, Keisuke
N1 - Funding Information:
Conflict of interest This work has been supported by the Practical Research Project for Allergic and Immunology from Japan Agency for Medical Research and Development, AMED (SS: grant number 18ek0510014h0003, YA: grant number 19ek0510023h0003). NU received speaker honoraria from Novartis Pharma Co. TI received research funding from Astellas Pharma, Chugai Pharmaceutical Co., and Kyowa kirin Co. FK received research support from Astellas Pharma and speaker honoraria from Novartis Pharma Co. JK received research support from Astellas Pharma and speaker honoraria from Astellas Pharma and Novartis Pharma Co. All other authors declare no competing financial interests.
Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2021/10/1
Y1 - 2021/10/1
N2 - Impact of donor age considering HLA disparity on hematopoietic cell transplantation (HCT) outcomes has not been fully evaluated. We evaluated 8486 patients who received unrelated bone marrow transplantation (UR-BMT) from 8/8 or 7/8 HLA-matched donors. Compared to 8/8 HLA-matched younger donors (<40 years), 8/8 HLA-matched older donors (subdistribution hazard ratio [SHR], 1.16; 95% CI, 0.97–1.38) and 7/8 HLA-matched younger donors (SHR, 1.33; 95% CI, 1.11–1.58) were associated with increased risk of grade III–IV acute graft-versus-host disease (aGVHD). 7/8 HLA-matched older donors had further increased risk (SHR, 2.00; 95% CI, 1.68–2.38) due to interaction between donor age and HLA disparity (p for interaction = 0.038). Progression-free survival (PFS) after UR-BMT with 8/8 HLA-matched younger donors was comparable to that after UR-BMT with 8/8 HLA-matched older donors, whereas UR-BMT with 7/8 HLA-matched younger or older donors was significantly associated with lower PFS than UR-BMT with 8/8 HLA-matched younger donors (younger donor; HR, 1.12; 95% CI, 1.04–1.21, older donor; HR, 1.28; 95% CI, 1.17–1.40; p for interaction = 0.079). In conclusion, adverse effect of increased donor age requires attention, especially in HLA-mismatched UR-BMT due to interaction between donor age and HLA disparity. Intensive aGVHD prophylaxis may be required to improve outcomes after HCT with mismatched older donors.
AB - Impact of donor age considering HLA disparity on hematopoietic cell transplantation (HCT) outcomes has not been fully evaluated. We evaluated 8486 patients who received unrelated bone marrow transplantation (UR-BMT) from 8/8 or 7/8 HLA-matched donors. Compared to 8/8 HLA-matched younger donors (<40 years), 8/8 HLA-matched older donors (subdistribution hazard ratio [SHR], 1.16; 95% CI, 0.97–1.38) and 7/8 HLA-matched younger donors (SHR, 1.33; 95% CI, 1.11–1.58) were associated with increased risk of grade III–IV acute graft-versus-host disease (aGVHD). 7/8 HLA-matched older donors had further increased risk (SHR, 2.00; 95% CI, 1.68–2.38) due to interaction between donor age and HLA disparity (p for interaction = 0.038). Progression-free survival (PFS) after UR-BMT with 8/8 HLA-matched younger donors was comparable to that after UR-BMT with 8/8 HLA-matched older donors, whereas UR-BMT with 7/8 HLA-matched younger or older donors was significantly associated with lower PFS than UR-BMT with 8/8 HLA-matched younger donors (younger donor; HR, 1.12; 95% CI, 1.04–1.21, older donor; HR, 1.28; 95% CI, 1.17–1.40; p for interaction = 0.079). In conclusion, adverse effect of increased donor age requires attention, especially in HLA-mismatched UR-BMT due to interaction between donor age and HLA disparity. Intensive aGVHD prophylaxis may be required to improve outcomes after HCT with mismatched older donors.
UR - http://www.scopus.com/inward/record.url?scp=85105956461&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85105956461&partnerID=8YFLogxK
U2 - 10.1038/s41409-021-01289-8
DO - 10.1038/s41409-021-01289-8
M3 - Article
C2 - 33990702
AN - SCOPUS:85105956461
SN - 0268-3369
VL - 56
SP - 2410
EP - 2422
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
IS - 10
ER -